Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis

Journal of Diabetes Investigation

Volumn 3, Issue 3, 2012, Pages 298-301

  Kume, Shinji ^a   Uzu, Takashi ^a   Takagi, Chieko ^b   Kondo, Morihiro ^b   Okabe, Tomoko ^b   Araki, Shin Ichi ^a   Isshiki, Keiji ^a   Takeda, Naoko ^a   Kondo, Keiko ^a   Haneda, Masakazu ^c   Koya, Daisuke ^d   Nishio, Yoshihiko ^a   Kashiwagi, Atsunori ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Rakuwakai Otowa Hospital   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

DPP 4; Hemodialysis; Vildagliptin

Indexed keywords

ALBUMIN; MITIGLINIDE; VILDAGLIPTIN; VOGLIBOSE;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PNEUMONIA; POSTPRANDIAL STATE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84861981033     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00169.x     Document Type: Article

References (13)

1. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007; 50: 1170-1177.
2. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
3. Haviv YS, Sharkia M, Safadi R. Hypoglycemia in patients with renal failure. Ren Fail 2000; 22: 219-223.
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
5. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-620.
6. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-658.
7. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007; 30: 3017-3022.
8. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30: 217-223.
9. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.
10. The committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1:212-228.
11. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
12. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
13. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009; 329: 669-676.